Abstract | BACKGROUND: METHODS: This retrospective single-center study reviewed the demographic and clinical data of 197 patients with primary FIGO stage III serous EOC who were treated with IDS with (n = 121) or without (n = 76, control group) dense HIPEC between January 2012 and April 2017. The co-primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoint was the occurrence of adverse events. RESULTS: The median PFS was 24 months in the IDS plus dense HIPEC group, whereas it was 19 months in the IDS alone group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.33-0.65, p = 0.000). The median OS in patients treated with IDS plus dense HIPEC (51 months) was significantly longer than that in patients treated with IDS alone (40 months, HR 0.52, 95% CI: 0.35-0.78, p = 0.001). The demographic and preoperative clinical characteristics of these two groups were comparable (p > 0.05). In the IDS alone group, no adverse events were recorded in 42 (55.3%) of the 76 patients, and 14 (18.4%) patients were reported to have grade III/IV adverse events. In the IDS plus dense HIPEC group, no adverse events were recorded in 55 (45.5%) of the 121 patients, and 23 (19.0%) patients were reported to have grade III/IV adverse events. No postoperative deaths occurred within 30 days in either group and neither did severe fatal complications in the IDS plus dense HIPEC group. CONCLUSIONS: IDS plus dense HIPEC with cisplatin in Chinese patients with FIGO stage III serous EOC is associated with improved survival and is reasonably well tolerated by patients.
|
Authors | Xiaoli He, Li Wei, Rui Li, Shuang Jing, Linlin Jia, Danwei Ji, Yali Li, Yue Wang, Yongxia Zhu |
Journal | BMC cancer
(BMC Cancer)
Vol. 21
Issue 1
Pg. 738
(Jun 27 2021)
ISSN: 1471-2407 [Electronic] England |
PMID | 34176478
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Carcinoma, Ovarian Epithelial
(drug therapy, mortality)
- Cisplatin
(pharmacology, therapeutic use)
- Female
- Humans
- Hyperthermic Intraperitoneal Chemotherapy
(methods)
- Neoplasm Staging
- Retrospective Studies
- Survival Analysis
|